Drug Profile
Research programme: aurora kinase inhibitors - vTv Therapeutics
Alternative Names: HPP607; TTP607; TTP9607Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics LLC
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV, Infusion)
- 24 Aug 2010 Preclinical development is ongoing in USA
- 20 Jul 2009 Preclinical development is ongoing in USA